Woah! Woah! Woah! Why the heck dose Dxm follow the normal dosage template here??? Dxm does not come in light, moderate, heavy, etc doses! If one is an experienced Dxm user they know the dose is heavily based off of body weight and the desired plateau! I must fix this, this dosage info is a disgrace to William Whites Dxm FAQ! Just kidding I'm being overly dramatic but seriously I'm gonna change that along with the description of the plateaus. Anyone else agree?
Hey there, thanks for the advice! I encourage you to change it however you wish. :) I agree that plateaus should be listed and have quickly edited the DXM substancebox template to reflect this. https://psychonautwiki.org/wiki/Template:SubstanceBox/DXM --Oskykins (talk) 15:54, 20 January 2016 (UTC)
I'll preface this by saying I am not suggesting Wikipedia be cited as a source, but if the sources Wikipedia cites in this case could be verified as accurate and credible and consulted to contain said information, the following could be added under "Drug Interactions" for harm reduction purposes. Apparently, Bupropion (Wellbutrin), which is both dopaminergic and affects norepinephrine, but not serotonergic, is purported to interact with dextromethorphan and thus, lower the seizure threshold because a metabolite of bupropion is a strong inhibitor of the enzyme that metabolizes dextromethorphan.
"...because bupropion is itself a strong inhibitor of CYP2D6 (Ki = 21 μM), as is its active metabolite, hydroxybupropion (Ki = 13.3 μM), it can slow the clearance of other drugs metabolized by this enzyme. As an example, the ratio of dextromethorphan (a drug that is mainly metabolized by CYP2D6) to its major metabolite dextrorphan increased approximately 35-fold when it was administered to people being treated with 300 mg/day bupropion, indicative of a major drug interaction with a common over-the-counter medicine."
Purported sources:  "Zyban 150 mg prolonged release film-coated tablets – Summary of Product Characteristics (SPC)". electronic Medicines Compendium. GlaxoSmith
 "Prexaton Bupropion hydrochloride PRODUCT INFORMATION". TGA eBusiness Services. Ascent Pharma Pty Ltd. 2 October 2012. Retrieved 22 October 2013.
 FDA Buproprion Label Last revised December 16, 2014 as described on the FDA Label Website. See that site for updates. Page accessed April 8, 2016
 Dwoskin LP, Rauhut AS, King-Pospisil KA, Bardo MT (2006). "Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent". CNS Drug Rev. 12 (3–4): 178–207. doi:10.1111/j.1527-3458.2006.00178.x. PMID 17227286.
 Jefferson JW, Pradko JF, Muir KT (November 2005). "Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations". Clin Ther. 27 (11): 1685–95. doi:10.1016/j.clinthera.2005.11.011. PMID 16368442.